GAITHERSBURG, Md. - Members of an FDA advisory committee voted unanimously in favor of bringing Tysabri (natalizumab) back to the multiple sclerosis market, but with restrictions. (BioWorld Today)
GAITHERSBURG, Md. - Members of an FDA advisory committee voted unanimously in favor of bringing Tysabri (natalizumab) back to the multiple sclerosis market, but with restrictions. (BioWorld Today)
GAITHERSBURG, Md. - Biogen Idec Inc. unveiled details of its risk-management strategy for Tysabri (natalizumab), a proposed plan that generally received support from the FDA and multiple sclerosis patients, during the first day of a two-day public hearing on the once-heralded MS drug. (BioWorld Today)
The French firm NicOx SA stands to break the bank, to the tune of up to nearly $400 million, per terms of a technology deal with Pfizer Inc. (BioWorld International)
GAITHERSBURG, Md. - Biogen Idec Inc. unveiled details of its risk-management strategy for Tysabri (natalizumab), a proposed plan that generally received support from the FDA and multiple sclerosis patients, during the first day of a two-day public hearing on the once-heralded MS drug. (BioWorld Today)
The French firm NicOx SA stands to break the bank, to the tune of up to nearly $400 million, per terms of a technology deal with Pfizer Inc. (BioWorld International)
